Page 2 - Nasdaq Arct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ExodusPoint Capital Management LP lessened its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 29.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,176 shares of the biotechnology company’s stock after selling 8,988 shares during the period. […]

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report)’s share price traded down 4.8% during trading on Monday . The company traded as low as $23.56 and last traded at $23.67. 76,757 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 431,716 shares. The stock had previously closed […]

HC Wainwright restated their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT – Free Report) in a research note released on Tuesday, Benzinga reports. HC Wainwright currently has a $51.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Arcturus Therapeutics’ FY2026 earnings at ($0.03) EPS and FY2027 earnings at $6.40 […]

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has been given a consensus recommendation of “Buy” by the four ratings firms that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock […]

HC Wainwright reaffirmed their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT – Free Report) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $51.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Arcturus Therapeutics’ FY2027 earnings at $6.10 EPS. Several other research firms […]